Rocket Pharmaceuticals, Inc. (RCKT)

Rocket Pharmaceuticals, Inc. (RCKT) Healthcare & Pipeline Overview

Rocket Pharmaceuticals, Inc. is a multi-platform biotechnology firm specializing in gene therapies for rare and devastating diseases. With clinical-stage ex vivo lentiviral vector programs and in vivo adeno-associated virus programs, Rocket Pharmaceuticals targets unmet needs in genetic disorders, positioning itself within the competitive biotechnology landscape.

What Is the Investment Thesis for RCKT?

Rocket Pharmaceuticals presents a notable research candidate within the biotechnology sector, driven by its focus on gene therapies for rare diseases. The company's clinical-stage programs targeting Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease represent significant potential for addressing unmet medical needs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and commercialization of its gene therapy products. The company's market capitalization of $443.87M reflects its current valuation, while a beta of 0.57 indicates lower volatility compared to the broader market. Upcoming catalysts include data readouts from ongoing clinical trials and potential partnerships or collaborations. Potential risks include clinical trial failures, regulatory hurdles, and competition from other gene therapy developers. Rocket Pharmaceuticals' ability to navigate these challenges and execute its development strategy will be critical to its long-term success.

Based on FMP financials and quantitative analysis

RCKT Key Highlights

• Rocket Pharmaceuticals focuses on gene therapies for rare diseases, addressing significant unmet medical needs.
• The company has multiple clinical-stage programs targeting Fanconi Anemia, LAD-I, PKD, and Danon Disease.
• Rocket Pharmaceuticals leverages both ex vivo and in vivo gene therapy technologies.
• The company has established license agreements with leading research institutions.
• Rocket Pharmaceuticals has a market capitalization of $443.87M as of 2026-05-10.

Who Are RCKT's Competitors?

RCKT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RCKT's Key Strengths?

• Proprietary gene therapy platform.
• Clinical-stage programs targeting rare diseases.
• Strong intellectual property portfolio.
• Experienced management team.

What Are RCKT's Weaknesses?

• High research and development costs.
• Dependence on clinical trial success.
• Regulatory hurdles and uncertainty.
• Limited commercialization experience.

What Could Drive RCKT Stock Higher?

• Data readouts from ongoing clinical trials for Fanconi Anemia, LAD-I, PKD, and Danon Disease programs.
• Potential regulatory submissions for gene therapy products.
• Advancements in manufacturing technologies to improve production efficiency.
• Strategic partnerships and collaborations to expand pipeline and market reach.

What Are the Key Risks for RCKT?

• Financial-distress signal — its Altman Z-Score of -3.83 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-70.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of gene therapy products.
• Competition from other gene therapy developers.
• High research and development costs.
• Intellectual property challenges.

What Are the Growth Opportunities for RCKT?

• Expansion into New Therapeutic Areas: Rocket Pharmaceuticals has the opportunity to leverage its gene therapy platform to expand into new therapeutic areas beyond its current focus on Fanconi Anemia, LAD-I, PKD, and Danon Disease. By identifying additional rare diseases with unmet medical needs, the company can broaden its pipeline and increase its potential market reach. The market size for gene therapies is projected to reach billions of dollars in the coming years, offering significant growth potential for Rocket Pharmaceuticals. This expansion could occur within the next 3-5 years as new targets are validated and clinical programs are initiated.
• Strategic Partnerships and Collaborations: Rocket Pharmaceuticals can pursue strategic partnerships and collaborations with other biotechnology companies, pharmaceutical companies, or academic institutions to accelerate the development and commercialization of its gene therapy products. These partnerships can provide access to new technologies, funding, and expertise, enhancing the company's capabilities and reducing its risk. Collaborative agreements could be established within the next 1-2 years, leading to accelerated clinical development timelines and increased market penetration.
• Geographic Expansion: Rocket Pharmaceuticals can expand its geographic reach beyond the United States and Europe to target emerging markets with significant unmet medical needs. By establishing a presence in these markets, the company can access new patient populations and increase its revenue potential. Geographic expansion could begin within the next 2-3 years, with a focus on regions with favorable regulatory environments and healthcare infrastructure.
• Advancements in Manufacturing Technologies: Rocket Pharmaceuticals can invest in advancements in manufacturing technologies to improve the efficiency and scalability of its gene therapy production processes. By optimizing its manufacturing capabilities, the company can reduce its production costs and increase its supply capacity, enabling it to meet the growing demand for its products. These advancements could be implemented within the next 1-2 years, leading to improved profitability and market competitiveness.
• Orphan Drug Designations and Regulatory Exclusivity: Rocket Pharmaceuticals can leverage orphan drug designations and regulatory exclusivity to protect its gene therapy products from competition. Orphan drug designation provides incentives such as tax credits, market exclusivity, and expedited regulatory review, enhancing the commercial attractiveness of the company's products. The company can pursue orphan drug designations for its gene therapy programs targeting rare diseases, securing a competitive advantage in the market. These designations can be obtained within the next 1-2 years, providing long-term market protection.

What Opportunities Does RCKT Have?

• Expansion into new therapeutic areas.
• Strategic partnerships and collaborations.
• Geographic expansion into emerging markets.
• Advancements in manufacturing technologies.

What Threats Does RCKT Face?

• Competition from other gene therapy developers.
• Clinical trial failures.
• Regulatory setbacks.
• Patent challenges.

What Are RCKT's Competitive Advantages?

• Proprietary gene therapy technologies.
• Strong intellectual property protection.
• Focus on rare diseases with limited competition.
• Established relationships with leading research institutions.

What Does RCKT Do?

Rocket Pharmaceuticals, Inc. is a biotechnology company dedicated to developing gene therapies for rare and devastating diseases. Founded with the mission of transforming the lives of patients with limited or no treatment options, Rocket Pharmaceuticals has built a multi-platform approach leveraging both ex vivo and in vivo gene therapy technologies. The company's pipeline includes clinical-stage programs targeting Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease. These programs utilize lentiviral vectors and adeno-associated viruses to deliver therapeutic genes directly to affected cells, aiming to correct the underlying genetic defects. Rocket Pharmaceuticals' research and development efforts are supported by license agreements with leading research institutions, including Fred Hutchinson Cancer Research Center and REGENXBIO, Inc. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals operates with a team of approximately 299 employees, focused on advancing its gene therapy programs through clinical development and towards commercialization. The company's commitment to innovation and patient-centricity drives its efforts to address the unmet medical needs of individuals with rare genetic disorders.

What Products and Services Does RCKT Offer?

• Develops gene therapies for rare diseases.
• Focuses on genetic disorders with unmet medical needs.
• Utilizes ex vivo lentiviral vector programs.
• Employs in vivo adeno-associated virus programs.
• Targets Fanconi Anemia, LAD-I, PKD, and Danon Disease.
• Conducts clinical trials to evaluate the safety and efficacy of its gene therapies.
• Seeks regulatory approvals for its gene therapy products.
• Collaborates with research institutions and other companies.

How Does RCKT Make Money?

• Develops and patents gene therapy technologies.
• Conducts preclinical and clinical research to validate its therapies.
• Out-licenses or commercializes its gene therapy products.
• Generates revenue through product sales and licensing agreements.

What Industry Does RCKT Operate In?

Rocket Pharmaceuticals operates within the biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The gene therapy market is experiencing substantial growth, driven by advancements in vector technology and increasing clinical success. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms, all vying for market share in specific disease areas. Rocket Pharmaceuticals' focus on rare diseases positions it within a niche segment of the market, offering the potential for orphan drug designations and expedited regulatory pathways. The company's success depends on its ability to differentiate its gene therapy products and navigate the complex regulatory environment.

Who Are RCKT's Key Customers?

• Patients with rare genetic diseases.
• Healthcare providers who treat these patients.
• Hospitals and medical centers.
• Pharmaceutical companies through licensing agreements.

RCKT Valuation & Market Position

With a $443.87M market cap, Rocket Pharmaceuticals, Inc. sits in the small-cap segment of the market. Relative to its peer group, RCKT's quantitative score of 24/100 is below the peer average of 67/100.

FY2026 estForward Outlook

Wall Street analysts project Rocket Pharmaceuticals, Inc. revenue of about $2.3M for fiscal 2026, with EPS near $-0.20. The estimate reflects 8 contributing analysts.

F-Score 1/9Financial Health

Rocket Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.83 places it in the distress zone, a signal of elevated financial risk.

ROE -71%Key Financial Metrics

Return on equity for Rocket Pharmaceuticals, Inc. stands at -70.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -73.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -50.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -57.6%, the inverse of the P/E and a quick read on earnings relative to price.

RCKT Financials

RCKT Latest News

RCKT Analyst Consensus

RCKT MoonshotScore

Latest Rocket Pharmaceuticals, Inc. Analysis

Common Questions About RCKT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources